Whitepapers

Medicine is more complex and barriers to access are expanding. Clinical guidelines, reimbursement pathways, and growing consumerism all influence access to medicine. There is a greater demand for data and transparency to help Providers, Payors, and Patients make informed decisions ensuring everyone wins. Medical Affairs generates evidence, develops a clear narrative, and delivers the information directly to the key decision makers who can remove those barriers to access...

...we must from time to time take stock of the trajectory upon which cancer therapy seems destined to follow.  Why?...

The market for precision medicine has grown exponentially and continues to grow. Precision medicine considers individual patient characteristics such as their genes, environments and lifestyles to provide tailored treatment options. In this article, we explore the key areas relevant to the economic evaluation of precision medicines and offer practical modelling recommendations based on our experience.

Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncologic drug development.1 As the next generation of tumour-agnostic therapies make their way through clinical trials, we should be asking ourselves what we can do to prepare for the upcoming challenge of reimbursement in this space, and what lessons can be learnt from the experience of existing therapies. Over the coming months, we will provide recommendations from our own experience and a review of the experiences of the tropomyosin receptor kinase (TRK) inhibitors larotrectinib and entrectinib to learn how to overcome the common challenges in this space. Here, in the second of our five-paper series, we focus on the difficulties of estimating the effectiveness of tumour-agnostic treatments in practice.